In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report), with a price target of $4.00. The company’s shares opened today at $1.60.
Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Virpax Pharmaceuticals, and Galmed Pharmaceuticals. According to TipRanks, Rahman has an average return of -25.9% and a 26.67% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Virpax Pharmaceuticals with a $4.00 average price target.
VRPX market cap is currently $19.68M and has a P/E ratio of -1.09.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
Read More on VRPX: